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ABSTRACT

TAF2: A POTENTIAL ONCOGENE FOR HEPATOCELLULAR
CARCINOMA
By SARANYA CHIDAMBARANATHAN REGHUPATY, B.Tech.
A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science Virginia Commonwealth University, 2017.
ADVISOR: DR. DEVANAND SARKAR, M.B.B.S., Ph.D.
Associate Professor, Department of Human and Molecular Genetics
Harrison Foundation Distinguished Professor in Cancer Research
Blick Scholar
Associate Scientific Director, Cancer Therapeutics
VCU Institute of Molecular Medicine
Associate Director of Education and Training
Massey Cancer Center

Astrocyte Elevated Gene 1 (AEG1) is an oncogene for hepatocellular carcinoma (HCC). Its role
in HCC pathogenesis has been well studied. A pan cancer analysis of gene expression in multiple
databases identified TATA-box binding protein associated factor 2 (TAF2) as the gene that is
most frequently co-expressed with AEG1. TAF2 is a protein that is involved in transcription of
genes by RNA polymerase II. It is a factor that is dispensable for basal transcription but, required
for activated transcription. It has also been shown to be involved in regulating cyclin levels and
hence cell cycle progression. Bioinformatic analysis on data from different cancer databases
confirmed the positive correlation of TAF2 expression with AEG1 expression, the over expression

of TAF2 in HCC patients and poor survival of HCC patients with increasing TAF2. We confirmed
the over expression of TAF2 in HCC cell lines using western blotting and HCC liver using
immunohistochemistry. We established cell lines with stable knockdown of TAF2

expression. These clones showed significant decrease in their ability to invade and migrate but
not their proliferation ability. This is in contrast to what has been observed in previous studies.
We hypothesize that the knockdowns do not show any decrease in cellular proliferation since the
remaining TAF2 in the cells is sufficient to produce cyclins and keep cell cycle undisturbed. The
knockdown of TAF2 causes an increase in E-cadherin level and decrease in Snail protein
expression which is a known negative regulator of E-cadherin. Knockdown of TAF2 causes cells
to become more epithelial leading to a decrease in their ability to migrate and invade. This study
shows that TAF2 is a potential oncogene that needs to be further studied.

CHAPTER 1
INTRODUCTION

THE PROCESS OF TRANSCRIPTION
All cells in our body, except germ cells and red blood cells, have the same set of DNA
fragments enclosed within their nucleus. But, brain cells are structurally and functionally
different from liver cells. What makes two cells with the same genetic composition
different from each other is the way their genes are expressed. A gene is a part of a DNA
segment that provides instructions in the form of a linear sequence of nucleotides to code
for an mRNA. This mRNA is then translated to produce a protein. Gene expression is
thus a two-step process involving transcription and translation. In some cases, such as
ribosomal RNAs, RNA is the final product of the gene. Hence, translation of the RNA to
a polypeptide does not occur. Cells do not require all of their gene products, be it RNA or
proteins, at all times. Only a subset of its genes is actively being expressed at any given
point of time. This difference in gene expression differentiates one cell type from the other.

Transcription is the first step in gene expression, wherein RNA is synthesized from a DNA
template. Tight regulation of transcription is essential to controlling gene expression 1.
Transcription is carried out by the nuclear enzyme RNA polymerase (RNAP). Prokaryotes
have a single RNAP enzyme that catalyzes the transcription of all of its genes whereas
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eukaryotes have three RNAPs each involved in the synthesis of different types of RNA2.
RNAPI transcribes ribosomal RNAs (rRNAs)3. RNAPII is responsible for the synthesis of
mRNA precursors and non-coding RNAs like snRNA4 and microRNA5. RNAPIII
transcribes small RNAs like transfer RNAs (tRNAs)6. RNAPII is the extensively studied of
all three RNAPs since it is involved in the transcription of protein-coding genes.

Transcription occurs in three stages-Initiation, elongation and termination. Initiation of
transcription takes place when RNA polymerase binds to the promoter region of a gene
and unwinds the double stranded DNA at the transcription start site. During elongation,
RNA polymerase travels along the template DNA strand in the 5’ to 3’ direction, adding
nucleotides to the 3’ end of the growing RNA strand 7. The steps involved in termination
of transcription differ for each RNA polymerase. Pre-mRNA transcripts produced by
RNAPII have a unique polyadenylation signal (AAUAAA) at the 3’ end. As RNAPII creates
this polyadenylation signal, it is recognized by two protein complexes CPSF (Cleavage
and Polyadenylation Specificity Factor)8 and CSTF (Cleavage Stimulation Factor)9,10.
These protein complexes then recruit other proteins to carry out RNA cleavage.

TRANSCRIPTION FACTORS
Transcription factors (TFs) are molecules that initiate and regulate the process of
transcription. They are protein complexes with DNA binding domains that allow them to
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bind to specific DNA sequences like promoters. They can also bind to enhancers or
repressors resulting in activation or repression of gene expression11. Certain genes have
varying levels of transcription. One is the basal transcription, which is usually a low level
of expression. It is also called minimal or constitutive expression. General transcription
factors are required for basal transcription and necessary for all genes. This low
expression level can be enhanced to reach a high level of transcription, called activated
transcription12. Activated transcription factors, unlike basal transcription factors, are gene
specific.

The initiation of transcription requires the binding of TFs to the core promoter element
resulting in the recruitment of the appropriate RNAP. Several core promoter elements
(CPEs) can bind these TFs to initiate transcription. The most important of these are TATA
box, Initiator (Inr) element and downstream core promoter element (DPE). The TATA box
was the first eukaryotic core promoter element to be identified. In metazoans, it is typically
located about 25-30 nucleotides upstream of the transcription start site. The consensus
sequence for the TATA box is 5’-TATAAA-3’13. The Initiator element is another core
promoter element that is located -6 basepairs upstream of the transcription start site and
continues to around +11 basepairs downstream. The consensus sequence for the Inr
element is YYANWYY14. The DPE is another core promoter element located about 28–
33 nucleotides downstream of the transcription start site. The DPE consensus sequence
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is RGWYV(T)15. These CPEs can be present by themselves or in combination with other
CPEs. For example, DPE and Inr elements are found in many promoters that lack TATA
box. There are also promoters that contain these elements in addition to the TATA box.
Approximately twenty four percent of human genes have a TATA-like element in their
promoter. But, only ten percent of these TATA-containing promoters have the canonical
TATA box. Forty six percent of human core promoters contain the consensus INR and
thirty percent are INR-containing TATA-less genes. Forty six percent of human promoters
lack both TATA-like and consensus INR elements16.

The RNAP II transcription machinery is extremely complex made up of more than 70
polypeptides. It involves, in addition to transcription factors, several cofactors and
mediators that aid RNAPII enzyme in transcription 17-19. RNA polymerase II preinitiation
complex is a 31 protein 1.5 megadalton protein complex. The formation of this complex
is important to initiate the process of transcription20-22. It is a sequential process involving
the binding of several General Transcription Factors (GTFs) to the promoter sequence 23.
The first of these steps is the recognition and binding of the GTF Transcription Factor IID
(TFIID) to the core promoter element. Once TFIID is bound, it recruits TFIIA and then
TFIIB. Once these three GTFs are bound, RNA polymerase and TFIIF are recruited.
Finally TFIIE and TFIIH are recruited completing the preinitiation complex formation 24.
TFIID is the largest of the GTFs involved in eukaryotic transcription. It is a complex made
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up of TATA binding protein (TBP) and several associated factors called TBP associated
factors (TAFs). TBP is the specific subunit that binds to the TATA box whereas TAFs are
coactivators of transcription.

TATA-BOX BINDING PROTEIN (TBP) ASSOCIATED FACTORS (TAFs)
When GTFs were identified, TFIID was found to bind unambiguously to the TATA box. It
was the only GTF that had sequence-specific DNA binding activity. TBP was the first
constituent of TFIID to be cloned. Purified TBP was able to replace TFIID and assemble
the PIC in vitro25. It was initially believed that TBP and TFIID were identical. However, it
was soon found that TBP was sufficient for basal transcription, but unable to support
activated transcription26,27. Biochemical fractionation of TFIID revealed that TBP had
coactivators associated with it and formed a large, stable multi-subunit complex. When
this whole complex was used, activated transcription was achieved. It was thus concluded
that TFIID comprises not only TBP, but also TBP-associated factors (TAFs). TAFs are
not a requirement for basal transcription but are necessary for activated transcription.
They are dispensable for the activation of specific genes 28. For example, eighty four
percent of yeast genes are dependent upon one or more TAFs for their transcription
whereas the remaining sixteen percent are TAF independent 29. Till date, approximately
13 TAFs have been identified so far that vary greatly in size from as low as 15 KDa to as
high as 250 KDa30.
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TAFs have been cloned and characterized in Yeast 31,32, Drosophila33-35 and
Humans27,36,37 revealing that they are evolutionary conserved35,38. All three species have
various shared sequence motifs, such as WD40 repeats (yTAFII90/dTAFII80/hTAFII100),
as well as limited sequence homology to histones H3 (yTAFII17/dTAFII40/hTAFII31), H4
(yTAFII60/dTAFII60/hTAFII70), and H2B (yTAFII61/dTAFII30α/hTAFII20)39. Interestingly,
human TAFII130 and Drosophila TAFII110 lack an obvious yeast homolog, suggesting
that the yeast and metazoan TFIID complexes, despite their many similarities, may
nevertheless differ in functionally important respects.

ASSEMBLY OF TAFs
TFIID is a twenty-subunit complex made up of 14 different polypeptides - TBP and 13
TAFs. TAFs are present in single copies or two copies in the TFIID complex. The complex
is composed of one copy of TBP and TAFs 1, 2, 3, 7, 8, 11 and 13 and two copies of
TAFs 4, 5, 6, 9, 10 and 12. Five of the six TAFs that are present in two copies (TAF4, 5,
6, 9 and 12) form a two-fold symmetric scaffold. TAF8 dimerises with TAF10 to form a
TAF8–TAF10 complex in the cytoplasm. This is imported into the nucleus by importins.
Binding of one copy of TAF8–TAF10 breaks the symmetry in core-TFIID, resulting in an
asymmetric complex. It exhibits two distinct halves and new binding surfaces for further
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subunits. Accretion of remaining TAFs and TBP in single copy, results in asymmetric
clamp shaped holo-TFIID that nucleates the preinitiation complex (Fig. 1.1)40. A key
feature in TAFs is the histone fold domain (HFD), which is present in nine out of 13 TAFs
in TFIID. The HFD is a strong protein-protein interaction motif that mediates specific
dimerization41.

TATA BOX BINDING PROTEIN ASSOCIATED FACTOR 2 (TAF2)
TAF2 is one of these several TAFs and has been shown to be homologous between
Yeast (TAF150 or TMS1), Drosophila (dTAFII150) and Mammals (TAF2, CIF150 or
hTAFII150)42,43. This 150 KDa protein forms a trimer with TAF1 and TBP and binds
specifically to the Initiator (Inr) element found at the transcription start site of many
genes42,44. An endogenous trimer made up of TAF2, TAF8 and TAF10 has been identified
suggesting that this sub complex subsequently binds with other TAFs to form the
complete PIC45. Tomography experiments have suggested that TFIID complex can alter
between four different conformations and binding of TAF2 stabilizes TFIID in a particular
conformation46. As with other TAFs, TAF2 is not universally required for transcription.
Only 3 percentage of yeast genome is dependent on TAF2 for transcription29. Some of
the potential TAF2 targets that have been identified include ribosomal proteins L44, S10
and L7a, ISGF-3, metallothionein II and lipid kinase47. It is also involved in the expression
of cyclins A and B1. Temperature sensitive TAF2 mutations in yeast and transient
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knockout of TAF2 in mammalian cell lines both led to cell cycle arrest in the G2/M
phase47,48.

ROLE OF TRANSCRIPTION FACTORS IN CANCER
Cells are the basic building blocks that make up every living system. For an organism to
grow and function normally, it is important that their cells divide and duplicate in an
organized manner. Cell division refers to the series of events that a cell goes through to
produce two daughter cells. It is made up of the interphase and the mitotic phase.
Interphase is the phase in which cells spend most of their life. It is made of G1, S and G2
phases. During the G1 phase, the cells prepare to duplicate its DNA. DNA gets duplicated
during S phase and the cells prepare for mitosis during G2 phase. Once the cells pass
through interphase the mitotic phase begins. This is when cells share the duplicated DNA
equally between two daughter cells. Mitosis is made up of prophase, prometaphase,
metaphase, anaphase and telophase. After mitosis, some cells enter the G0 phase where
they are in a quiescent state. Some cells like nerve cells and red blood cells that are
terminally differentiated stay in this phase since there is no need for them to divide again.
Adult mature hepatocytes are unique in that they stay in G0 phase until a regenerative
process is initiated due to tissue loss or intoxication.

The three checkpoints - G1, G2 and M make sure that the cell stalls its division if the
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conditions are not right. Once the cells go through the G1 checkpoint, they are irreversibly
committed to division. The G2 checkpoint makes sure that the DNA produced after
replication is free of damage. If there is any kind of damage to the DNA, the DNA damage
repair mechanism fixes the damage before the cell moves to mitosis. The M checkpoint
makes sure that all sister chromatids are correctly attached to the spindle microtubules
before they are pulled towards the pole during anaphase. Several proteins are involved
in keeping the cell cycle under control. An aberration in the level of these proteins can
disrupt this control. When this process of cell cycle is perturbed, abnormal cell growth
occurs. This is the primary difference between a normal cell and a tumor and explains the
simplest definition of cancer, which is uncontrolled cell division.

Several proteins are involved in this process of transforming a normal cell into a tumor. A
broad way of classifying these proteins is as oncoproteins and tumor suppressor proteins.
Oncoproteins enhance cell division and viability. In a cancer cell, these proteins are
overexpressed causing abnormal cell division. On the other hand, tumor suppressor
proteins, that are required to slow down cell division and promote cell death are down
regulated in a cancerous state. Transcription factors have an important role to play in
producing these RNAs and proteins at optimum levels. Changes in levels of these
transcription factors can lead to abnormal cell division causing cancer.
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HEPATOCELLULAR CARCINOMA
The liver is made up of four different types of cells namely hepatocytes, kupffer cells,
stellate cells and liver sinusoidal cells. Of these four cell types, hepatocytes are the major
functional cells and make up 75 percent of the liver. A cancer caused due to malignant
tumors originating in these cells is called hepatocellular carcinoma (HCC). HCC is the
most common primary liver cancer. Approximately 70 to 90 percent of liver cancers are
HCC49. According to Globocan 2012, it is the fifth most common cancer in men and the
ninth common cancer in women worldwide. It is the second most common cause of death
from cancer worldwide. The overall ratio of mortality to incidence is 0.95. The similarity
between the incidence and mortality reflects the poor prognosis of this disease.

HCC risk factors
Most patients with HCC have liver cirrhosis49. It is a condition in which the hepatocytes
slowly lose their proliferation capacity, preventing the liver from regenerating. As a result,
scar tissue replaces the healthy liver tissue and partially blocks the flow of blood to the
liver. The development of cirrhosis is a slow and gradual process. In the early stages of
cirrhosis, the liver continues to function. But with worsening cirrhosis, the liver fails. HCC
can develop anytime during the progression of liver cirrhosis50. Telomerase dysfunction
and alterations in the micro and macro environment that stimulate cellular proliferation
are some of the ways in which liver cirrhosis can lead to HCC51.
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HBV infection is responsible for more than 50 percent of HCC cases worldwide52. HBV is
a partially double-stranded DNA-containing virus belonging to the Hepadnaviridae family.
In most cases, HBV infection can cause cirrhosis and eventually HCC. However, HBV
can also cause HCC in the absence of cirrhosis. HBV can integrate its DNA into host cells
and act as a mutagenic agent causing HCC53.
HCV infection is another risk factor of HCC and accounts for approximately 30 percent of
HCC cases globally52. HCV is an RNA virus and unable to integrate into the host
genome54. Thus, HCV causes HCC exclusively through liver cirrhosis. HCV core protein
enters the host cell, where it localizes in the outer mitochondrial membrane and
endoplasmic reticulum and promotes oxidative stress. This results in the activation of key
signaling pathways leading to HCC55. Chronic hepatitis C is more aggressive in HIV
positive subjects, leading to cirrhosis and liver failure56.
Chronic alcohol consumption is another important risk factor for HCC. It leads to liver
damage through endotoxins, oxidative stress or inflammation causing HCC. It can also
have genotoxic effect by enhancing the expression of certain oncogene expression or
impairing the ability of cells to mend their DNA57. Chronic alcohol consumption can also
act as a cofactor for HCC development synergistically with other risk factors like viral
infections.
Another important HCC risk factor, especially in developing countries is Nonalcoholic
steatohepatitis (NASH). The major cause of NASH is obesity58. Obesity leads to non-
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alcoholic fatty liver disease, which in turn causes the inflammatory form non-alcoholic
steatohepatitis and in turn promotes HCC59. Other risk factors of HCC include aflotoxin
B1, pesticides, diabetes mellitus and diet57,60-62.

Trends in HCC incidence
There is a striking variation in HCC incidence rates between various countries. The
incidence rate is highest in developing countries particularly Eastern Asia and SouthEastern Asia, intermediate in Southern Europe and Northern America and lowest in
Northern Europe and South-Central Asia63. Although at a global level, the major burden
of HCC still falls on developing countries, HCC incidence has been decreasing in Asian
countries64. This decrease can be attributed to programs to reduce aflatoxin B1 exposure
and HBV transmission, declining rates of HCV infection in the population and other public
health efforts65. In contrast, developed countries like the US have been experiencing an
increase in HCC incidence66,67. Most of the increase in HCC cases can be attributed to
the aging cohort with chronic hepatitis C infection. Increasing incidence of obesity and
non-alcoholic fatty liver disease is another factor responsible for the rise in HCC
incidences in the US68,69.
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HCC treatment
Liver transplantation is the best treatment option for patients with late cirrhosis 70. Surgical
resection is another treatment option available for patients with a single nodule, no
cirrhosis and good liver function71,72. Local ablation with radiofrequency is the standard of
care for patients with very early and early stage tumors that are unsuitable for surgery 73.
Transcatheter arterial chemoembolization is a minimally invasive procedure that involves
administration of chemotherapy and embolization materials directly to a liver tumor via a
catheter to restrict a tumor’s blood supply. This is recommended for patients with
intermediate-stage HCC74. Sorafenib is the only approved chemotherapy drug to treat
HCC. It is an oral bi-aryl urea, which inhibits multiple cell surface and downstream kinases
involved in tumor progression. Two phase III randomized placebo-controlled trials, the
SHARP trial conducted mainly in America and Europe and a similar trial conducted in
Asia reported improved overall survival with sorafenib75,76. In the SHARP trial, the median
overall survival increased to 10.7 months with sorafenib compared to 7.9 months with
placebo76. HCC is usually detected at late stages and treatment options for late stage
HCC are minimum. This reveals the importance of finding new drug targets to develop
HCC drugs.

GENE AMPLIFICATION IN CANCER
Gene amplification is the increase in copy number of a restricted region of a chromosome
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arm. It a mechanism that cells use to overexpress certain genes for survival under stress
such as during exposure to cytotoxic drugs. Some of the proposed mechanisms for the
occurrence of gene amplification include extra replication and recombination, replication
fork stalling and template switching, the breakage and fusion bridge cycle and double
rolling circle replication77. It is frequently observed in some solid tumors and contributes
to tumor evolution. MYC was the first oncogene that was proven to be amplified in a
variety of tumor cells78-80. Later on, few chromosomal regions were found to be amplified
to a great extent in many cancers. One such chromosomal segment that is frequently
amplified in many cancers is the chromosomal region 8q47,48,81-84. This is the
chromosomal region that houses the MYC oncogene. The MYC oncogene is present in
the chromosomal region 8q24. Increasing evidence has shown that there are other
neighboring regions in the long arm of chromosome 8 that are amplified 85,86. 8q22 is one
such region that was identified87. One of the many oncogenes present in this gene is the
MTDH gene.

ASTROCYTE ELEVATED GENE-1 IN HCC
AEG-1/MTDH is an oncogene which is overexpressed in many common cancers88-92, and
its expression level negatively correlates with poor survival and overall adverse
prognosis93-96. AEG-1 overexpression induces an aggressive, angiogenic and metastatic
phenotype whereas knockdown of AEG-1 inhibits these phenotypes in all cancers studied
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so far. AEG-1 is transcriptionally regulated by c-Myc, an oncogene frequently upregulated
in HCC97. The tumor suppressor miRNA miR-375, which is downregulated in HCC
patients, targets AEG-198. In vitro and in vivo studies have shown that AEG-1 modulates
expression of genes associated with proliferation, invasion, chemoresistance,
angiogenesis and metastasis, and activates multiple pro-tumorigenic signaling
pathways99. These studies indicate that AEG-1 is a valid target for HCC therapeutic
development.

TAF2 IN CANCER
The gene encoding the protein TAF2 is present in the chromosomal region 8q24.12. This
region is a mutational hotspot and is frequently amplified in a variety of cancers. The first
association between TAF2 and cancer emerged in 2014 when cBioPortal for cancer
genomics was used to analyse TAF alterations in cancer. It was found that TAF2 exhibits
copy number increases or mRNA overexpression in 73% of high grade serous ovarian
cancer100. Other than overexpression, TAF2 is also hypomethylated in breast
carcinoma101. Though TAF2 has been hypothesized as an oncogene solely based on
bioinformatics data, no studies have looked at TAF2 in the context of cancer progression
so far. Research has been going for decades now to better understand the role of TAF2
in transcription. Though, the role of TAF2 in transcription at a molecular level has been
better understood, its role in cancer progression, the downstream targets, pathways
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regulated and interacting partners are yet to be unraveled.

CANCER HALLMARKS
Tumorigenesis refers to the production or formation of tumors. It is a multistep process,
the progression of which depends on a sequential accumulation of mutations within tissue
cells. Cancer is a manifestation of six essential alterations in cell physiology that
collectively dictate malignant growth (Fig. 1.2)102.

Self-sufficiency in growth signals
Cells of the body require molecules that act as signals for them to grow and divide. Cancer
cells, however, grow in the absence of growth stimulatory signals that normal cells require
from their environment. Cancer cells can do this by autocrine signaling, cell surface
receptor overexpression and integrin switching102.

Insensitivity to anti-growth signals
Cells have tight control over cell division. Tumor suppressor genes are important proteins
in this process. These genes halt cell division if the cell fails any of the three checkpoints.
In cancer, these tumour suppressor proteins are altered so that they don't effectively
prevent cell division, even when the cell has abnormalities. Cancer cells also do not have
contact inhibition, and will continue to grow and divide, regardless of their surroundings 103.
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Evasion of apoptosis
Apoptosis or programmed cell death is initiated by cells when they are damaged or
infected. This is required for organisms to grow and develop properly and for maintaining
tissues of the body. Cancer cells, however, lose their ability to undergo apoptosis even
though cells may be abnormal. The cancer cells may do this by altering the signals that
detect the damage or abnormalities and activate apoptosis. They may also have defects
in the downstream signaling itself, or the proteins involved in apoptosis104.

Limitless replicative potential
Cells of the body have a limited number of divisions before the cells stop division. This is
due to the DNA at the end of chromosomes, known as telomeres shortening with every
cell division. Once it reaches a particular length, it activates senescence and the cell stops
dividing. Cancer cells manipulate telomerases and maintain telomeres at a length above
the critical length105. Thus, they divide indefinitely, without initiating senescence.

Sustained angiogenesis
Normal tissues of the body require blood vessels running through them to deliver oxygen
from the lungs. Cells must be close to the blood vessels to get enough oxygen for them
to survive. An expanding tumor requires new blood vessels to deliver adequate oxygen
to the cancer cells, and produces new vasculature by activating the angiogenic switch 106.

17

In doing so, they control non-cancerous cells that are present in the tumor that can form
blood vessels by reducing the production of factors that inhibit blood vessel production,
and increasing the production of factors that promote blood vessel formation.

Tissue invasion and metastasis
Cancer cells have the ability to invade neighboring tissues. Tissue invasion is the reason
for their dissemination around the body. Cancer cells have to undergo a multitude of
changes in order to acquire the ability to metastasize. It is a multistep process that starts
with local invasion of the cells into the surrounding tissues, invasion of blood vessels,
enter the circulatory system and exit in a different site and start dividing107.

MIGRATION AND INVASION IN CANCER
Cancer metastasis is the cause of 90 percent of cancer related deaths108. It is the spread
of cancer cells to tissues and organs beyond the primary site of tumor formation. Cancer
cells can exploit their intrinsic migratory ability to invade nearby tissues and the
vasculature, and ultimately metastasize. Metastasis is a multi-step process that includes
dissociation-the process of a single tumor cell detaching from the primary tumor, invasionthe infiltration of the tumor cell to the stroma and invasion through the basement
membrane, intravastion-the entry of the tumor cell into the vasculature and extravasationthe exit of the tumor cell from the vasculature and entry into remote organs 108. Once the
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tumor cell enters the secondary organ, it can proliferate resulting in clinically detectable
tumor or remain dormant for years109. The cytoskeletal properties of the disseminating
tumor cells play an important role in its ability to metastasize successfully.
Migration begins with polarization and extension of a leading front in the direction of the
movement. Lamellipodia, filopodia, pseudopodia and invadopodia are different types of
cell protrusions formed by migrating cells110. These protrusions are formed by actin
polymerization. The leading front then binds to extracellular matrix proteins. This
attachment occurs by means of cell adhesion molecules (CAMs) such as integrins and
cadherins111. This binding causes the cell body to shrink which results in a traction force.
This force allows the cell body to slide behind the migrating front resulting in cell
movement. Actin-myosin contraction plays a major role in shrinking of the cell along the
long axis. Organization of the actin-myosin skeleton is controlled by different enzymes.
Myosin Light Chain kinase (MLCK) and Myosin Light Chain phosphatase (MLCP) are two
enzymes that act on the light chains of myosin. The activity of these enzymes, in turn, is
regulated by another set of enzymes, the Rho-GTPases. This group includes several
members like Rho, Rac and CDC42 proteins112.
As opposed to cell migration, invasion by tumor cells require the cells to degrade the
extracellular matrix. Matrix Metalloproteases are proteases that play an important role in
degrading the basement membrane and extra cellular matrix. Cytokines and growth
factors regulate the expression of MMPs through the mitogen-activated protein kinases

19

pathway that includes proteins such as ERK 1/2 (extracellular regulated kinase 1/2),
JNK/SAPK1/2 (c-Jun N-terminal kinase 1/2) and p38MAPK113,114.

EPITHELIAL-MESENCHYMAL TRANSITION (EMT)
Epithelial-mesenchymal transition (EMT) is a biologic process that allows a polarized
epithelial cell, which normally interacts with basement membrane via its basal surface, to
undergo multiple biochemical changes that enable it to assume a mesenchymal cell
phenotype, which includes enhanced migratory capacity, invasiveness, elevated
resistance to apoptosis, and greatly increased production of ECM components115,116.
EMT is under tight control of multiple regulatory pathways. Transforming growth factor β
(TGF-β) activity is usually enhanced during EMT117. Binding of TGF-β to its cell surface
receptors activates Smad family of transcription factors. These smad proteins translocate
to the nucleus and cooperate with transcription factors from the Snail and Twist family118.
TFG-β can also activate Rho-like GTPases119. These effectors repress genes that are
involved in cell polarity and cell-cell adhesion, such as RhoA and E-cadherin. At the same
time, the expression of N-cadherin, another member of the cadherin family that allows for
enhanced adhesion between mesenchymal cells, is upregulated. This change in cadherin
expression is called cadherin switch and is a hallmark of EMT 120.
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CHAPTER 2
MATERIALS AND METHODS

Cells and culture conditions
Hep3B cells were obtained from the American Type Culture Collection (Manassas, VA);
QGY-7703 cells were obtained from Fudan University, China; HepG3 and Huh7 cells
were kindly provided by Dr. Paul Dent. QGY-7703, HepG3 and Huh7 cells were cultured
in Dulbecco's Modified Eagle Media (DMEM). Hep3B cells were maintained in Minimum
Essential Media (MEM) alpha. RPMI 1640 media was used for culturing SNU-182 and
SNU-449. SK Hep-1 and PLC/PRF/5 cells were cultured in Eagle’s Minimum Essential
Media (EMEM). For generation of stable clones, Huh 7 and QGY-7703 cells transfected
with luciferase gene (QGY-7703 luc cells) were used. All the above media were
supplemented with 5% FBS and 0.5% penstrep.

Generation of stable clones
Huh7 and QGY-7703 luc cells were transfected with TAF2 shRNA (sc-77487-SH) or
control shRNA (sc-108060). Transfection was performed using lipofectamine 2000
(Invitrogen). 15 µl of lipofectamine reagent was diluted in 500 µl of Opti-MEM I reduced
serum medium. 8 µg of TAF2 or control shRNA was diluted in 500 µl of OPTI-MEM I
reduced serum medium. They were incubated for 5 minutes. Diluted DNA was added to
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diluted lipofectamine 2000 reagent (1:1 ratio). The mixture was incubated for 20 minutes
and added to a 6cm dish containing cells at 70 % confluency. After 48 hours, single cell
suspension was plated. Individual colonies were selected, expanded and maintained in
media containing 1 µg/ml puromycin.

Western blotting
Cells were washed twice with cold PBS and lysed on ice for 30 min in 250 ul of cold 1.5%
n-dodecyl -D-maltoside (DDM). Cell debris were removed by centrifugation at 15,000 rpm
for 15 min at 4°C. Protein concentrations were determined using the Bio-Rad protein
assay system. Aliquots of cell extracts containing 30 µg of total protein were resolved in
10% SDS-PAGE and transferred to nitrocellulose blotting membranes. Membranes were
blocked for 1 h at room temperature in Blocking buffer (5% nonfat milk powder in TBST:
10 mm TRIS-HCL (pH 8.0), 150 mm NaCl, 0.05% Tween 20), and then incubated
overnight at 4 degree Celsius in Blocking buffer containing the respective primary
antibody. After washing in TBST buffer thrice (10 min, RT), membranes were incubated
for 1 h at room temperature in the respective secondary antibody diluted in suitable
buffers. After washing in TBST, Enhanced Chemiluminescence(ECL) detection reagents
were used to detect the protein of interest.

q-RT-PCR
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Cells were lysed with 700 µl of QIAzol lysis reagent and homogenized by vortexing. 140
µl chloroform was added to separate RNA from DNA and proteins. Centrifugation at
15,000 rpm for 15 minutes at 4℃ was done to separate the solution into three phases.
The RNA in the upper aqueous phase was transferred to a new collection tube and 1.5
volumes of 100% ethanol was added to precipitate the RNA out of the solution. The
solution was pipetted into an RNeasy Mini column and centrifuged. The filter was then
washed with wash buffers RWT and RPE (twice). The membrane was further dried by
centrifuging at full speed for 1 minute. RNA was eluted using 50 µl RNase free water.
Concentration of RNA was measured using the bio rad system. cDNA was synthesised
from the extracted RNA by making a master mix composed of 2 µg RNA, 2 µl 10X buffer,
2 µl random primers, 6.4 µl dNTP, 1 µl RNase out and 1 µl reverse transcriptase. The
volume was made upto 20 µl using RNase free water. cDNA synthesis was performed
using PCR. The cDNA was then probed with TAF2 or GAPDH probe.

Colony formation assay
500 cells were plated in a 6cm dish. After two weeks, the cells were fixed (with 3.7%
formaldehyde) and stained (with 25% giemsa). The number of colonies (>50 cells) were
counted. Colony forming ability was calculated as
(Number of colonies counted/Number of cells plated) * 100

23

MTT assay
1000 cells were plated in a each well of a 96 well plate. At the desired time point, (3-(4,5Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) reagent was added to the
media. After 5 hours, equal volume of sodium dodecyl sulphate (SDS) was added. The
plates were incubated at 37°C overnight. Absorbance was measured at 600 nm.
Readings were obtained at 24, 48, 72 and 96 hours.

Migration assay
A wound healing/scratch assay was used to evaluate cell migration. Confluent cells were
scratched with a 200 μl micropipette tip to create a cell-free area. The scratched
monolayers images were captured at 0, 24 and 48 hours after wounding. A mark was
made on the plates to make sure that the same area is being imaged everyday. The
wound width was measured at the specific time points and compared.

Invasion assay
Invasion was measured by using 24-well BioCoat cell culture inserts with an 8-μ-porosity
polyethyleneterepthalate membrane coated with Matrigel basement membrane matrix
(100 μg/cm2). Briefly, the Matrigel was allowed to rehydrate for 2 h at 37 °C. The wells of
the lower chamber were filled with medium containing 5% FBS. 25,000 cells were seeded
in the upper compartment (6.25-mm membrane size) in serum-free medium. The invasion
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assay was performed at 37 °C in a 5% CO2 humidified incubator for 22 hours. At the end
of the invasion assay, the filters were removed, fixed (with methanol), and stained (with
10% crystal violet). Cells on the upper surface of the filters were removed by wiping with
a cotton swab, and invasion was determined by counting the number of cells that migrate
to the lower side of the filter with a microscope at 100X magnification.

IMMUNOFLUORESCENCE AND IMMUNOHISTOCHEMISTRY
Normal human liver and human HCC liver were fixed on a slide for immunohistochemistry.
For IF, primary hepatocytes, QGY-7703 cells and SNU-182 cells were plated on a 4chamber slide. The slides were blocked and incubated overnight in diluted TAF2 antibody.
They were rinsed the following day and treated with fluorochrome conjugated secondary
antibody. The amount of fluorescence was detected by confocal laser scanning
microscopy (LSM700). For IHC, secondary antibodies bound to horseradish peroxide
was used and peroxidase was used to obtain staining. The distribution of the stain was
observed under a microscope.

BIOINFORMATICS
Pan-cancer analysis of gene expression data in multiple databases was done to
determine the genes in 8q that correlate with AEG-1 expression in 38 different cancer
types.
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Liver cancer samples (LIHC, n = 371) from TCGA database were analyzed to determine
the genomic alterations in these patients in the TAF2 gene. The “R2: Genomics Analysis
and Visualization Platform” was used to determine the correlation between expression
levels of AEG-1/MTDH and TAF2 genes in two independent datasets. Oncomine was
used to compare TAF2 copy number differences between HCC samples and normal liver.
Two independent datasets, TCGA and Guichard, were used for this analysis. RNA
expression levels in three independent datasets (Roessler Liver 2, Wurmbach Liver, Chen
Liver) were also compared using Oncomine.
To understand the relationship between TAF2 expression levels and patient survival, a
Kaplan-Meier plot was obtained. Data from TCGA HCC database was used for this
analysis.
TCGA HCC (LIHC, n = 371) dataset was divided into two groups: TAF2 high (top 25%; n
= 93) and TAF2 low (bottom 25%; n = 93). R program was used to identify differentially
expressed genes between patients expressing high and low TAF2. A heat map of top 50
differentially modulated genes was also obtained.
Canonical pathway analysis by ingenuity software was used to identify genes that are
significantly upregulated and downregulated. These differentially changed genes were
analysed using Ingenuity pathway analysis software to identify the upstream regulators
that might lead to alterations in downstream genes. A z-score > 2 indicates activation and
a z-score<-2 indicates inhibition.
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STATISTICAL ANALYSIS
All results were checked for statistical significance using the one-way ANOVA test.
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CHAPTER 3
RESULTS

TAF2 overexpression positively correlates with AEG-1/MTDH over expression
Pan-cancer analysis of gene expression data in multiple databases which identified
TATA-box binding protein associated factor 2 (TAF2; 8q24) as the most frequently coexpressed gene with AEG-1 in 36 out of 38 different cancer types (Pearson’s correlation
coefficient r>0.5; p<3E-14). Analysis of liver cancer samples (LIHC, n = 371) from TCGA
database confirmed our observations that TAF2 is co-expressed with AEG-1/MTDH (r =
0.569, p<1E-16). Independent analysis using the “R2: Genomics Analysis and
Visualization Platform” further confirmed strong positive correlation between expression
levels of AEG-1/MTDH and TAF2 genes in two independent datasets (Fig. 2.1).

TAF2 gene is amplified and over expressed in human HCC patients
Analysis of TCGA database showed that TAF2 is amplified in approximately 20% of HCC
patients (Fig. 2.2a). In Oncomine, two independent datasets (TCGA and Guichard) on
HCC showed TAF2 copy number gain in HCC samples compared to normal liver (Fig.
2.2b). At mRNA expression level three independent datasets in Oncomine showed highly
significant increase in TAF2 mRNA levels in HCC samples versus normal liver (Table 1).
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Patient survival decreases with increasing TAF2 expression
We then used a Kaplan-Meier plot to determine the relationship between TAF2
expression and patient survival. A significantly strong negative correlation (p = 0.0041)
was observed between TAF2 expression levels and HCC (stages T2-T4) patient survival
in TCGA database (Fig. 2.3).

Genes involved in several oncogenic signaling pathways are upregulated in HCC
patients with increased TAF2
TCGA HCC dataset was divided into two groups-TAF2high and TAF2low. TAF2 showed
log2fold change of 2.27 in TAF2high vs TAF2low (p = 4.77E-65). A total of 8166 differentially
expressed genes were identified at false discovery rate (FDR) corrected p-value of 0.01.
5327 genes were upregulated while 2839 were downregulated. A heat map of top 50
differentially modulated genes shows tight clustering (Fig. 2.4a). Canonical pathway
analysis by ingenuity software identified significant upregulation of genes of several
oncogenic signaling pathways (such as ERK5, IGF-1 and HGF signaling) and marked
downregulation of genes in EIF signaling pathway and oxidative phosphorylation resulting
in mitochondrial dysfunction in TAF2 high group (Fig. 2.4b). Molecules involved in
oncogenic signaling pathways (CD24, MAP4K4, HGF, VEGF) and several miRNAs were
found to be possible upstream regulators of the differentially expressed genes. Activation
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of cyclin D1 (CCND1) and inhibition of RB1 were identified to cluster with TAF2 high
further indicating a role of TAF2 in regulating cell cycle.

TAF2 is overexpressed in HCC
Western blotting was done to detect TAF2 in primary hepatocytes and different HCC cell
lines. It was found TAF2 present in primary hepatocytes was undetectable on a western
blot. On the other hand, all the HCC lines that were used for analysis showed a much
higher level of TAF2 protein expression (Fig 2.5b). Immunofluorescence assay was done
to compare TAF2 expression levels between primary hepatocytes and HCC cell lines and
showed similar results as western blotting (Fig 2.5a). Liver sections from normal subjects
and HCC patients were used to compare the levels of TAF2 expression in vivo. It was
found that normal liver section had much lesser staining of TAF2 compared to HCC liver
(Fig 2.5c).

Knockdown of TAF2 does not affect proliferation
TAF2 was knocked down using shRNA. The knockdown was confirmed using western
blotting and q-RT-PCR. Two positive clones from Huh 7 cells showed a knockdown of 60
percent as compared to untreated cells (Fig 2.6a,c). The positive clone from QGY Luc
7703 cells showed a knockdown of 40 percent (Fig 2.6b,d). The clones were named
shTAF2-1 and shTAF2-2 and shTAF2-3 and used for further assays. The cells treated
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with control shRNA did not show any difference in TAF2 expression compared to
untreated cells and were named shCon-1 (Huh7 cells) and shCon-2 (QGY Luc cells).
MTT and colony formation assays were done to determine the effect of the knockdown
on proliferation. For MTT assay, the absorbance of the shCon and shTAF2 cells were
measured at 24, 48, 72 and 96 hours and compared. There was no significant difference
in proliferation between the cells (Fig 2.7 a,b).
For colony formation assay, the number of colonies were counted after 3 weeks for Huh7
cells and 2 weeks for QGY-7703 Luc cells. Representative plates after fixing and staining
are shown in fig 2.8 c. The shCon and shTAF2 cells did not show any difference in their
ability to form colonies (Fig 2.8 a,b).

Knockdown of TAF2 inhibits migration
Wound healing assay was done to determine if there was any difference in ability to
migrate between the cells. At 24 hours, the wound distance in both shTAF2-1 and
shTAF2-2 cells was higher compared to shCon-1 cells (p=0.0009 and p=0.0018). At 48
hours, the wound distance remained higher in shTAF2-1 and shTAF2-2 cells compared
to shCon cells (p=0.000385 and p=0.028501) (Fig 2.9 c). shTAF2-3 cells also showed a
higher wound distance compared to shCon-2 cells at 24 and 48 hours (p=0.021 and
p=0.041) (Fig 2.9 d).

31

Knockdown of TAF2 inhibits invasion
Matrigel invasion assay was done to determine any difference between shCon and
shTAF2 cells in their ability to invade the Matrigel. After fixing and staining, more cells per
field were observed in the shCon cells compared to shTAF2 cells (Fig 2.10 a). Upon
quantification, there was significant decrease in the number of shTAF2-1 (p=0.015727)
and shTAF2-2 (p=0.002568) cells that had invaded the Matrigel compared to shCon-1
cells. This result was also observed in shTAF2-3 cells (p=0.027155).

Knockdown of TAF2 does not affect cyclin A or cyclin B1 expression
To find out the reason for not observing a change in cellular proliferation in the TAF2
knockdowns, the knockdowns and control were probed for cyclins A and B1. shTAF2-1
and shTAF2-2 cells did not show any difference in cyclin levels as compared to shCon-1
cells.

Knockdown of TAF2 increases E-Cadherin and decrease Snail protein expression
The knockdowns and control were probed for EMT markers: E-Cadherin and N-Cadherin.
An increase in E-Cadherin was observed in the shTAF2-1 and shTAF2-2 cells compared
to shCon-1 cells. There was no change in N-Cadherin levels. The knockdowns were
probed for known regulators of E-Cadherin. Snail, which is a known negative regulator of
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E-Cadherin showed decrease in shTAF2-1 and shTAF2-2 compared to shCon-1 cells.
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CHAPTER 4
FIGURES

Figure 1.1: Model for holo-TFIID assembly

Figure 1.2: Hallmarks of cancer
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(a)

(b)

Figure 2.1: Positive correlation between TAF2 and AEG-1 expression in (a) tumor liver and (b)
mixed liver sample

(a)

(b)

Figure 2.2: TAF2 is amplified and exhibits copy number gain in HCC patients
(a) Analysis of TCGA database shows the alteration frequency of TAF2 in liver cancer patients.
(b) Analysis of TAF2 copy number alteration in HCC patients in TCGA and Guichard databases
shows increased TAF2 copy number in HCC samples
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Database

Liver(n)

HCC(n)

Log2 fold

p-value

Rank

Roessler Liver 2

220

225

1.954

3.88E-55

In top 3%

Wurmbach Liver

10

35

1.866

3.57E-7

In top 2%

Chen Liver

75

104

1.457

4.33E-9

In top 7%

Table 1: TAF2 mRNA expression in HCC patients and normal subjects in three
independent datasets

Figure 2.3: A Kaplan-Meier plot shows decreasing survival of HCC patients with
increasing TAF2 expression
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(a)

(b)

(c)

Figure 2.4: (a) A heat map showing top 50 differentially expressed (DE) genes in TAF2high
and TAF2low HCC patients. Canonical pathway analysis by ingenuity software showing
genes that are (b) upregulated and downregulated in TAF2high group and (c) potential
upstream regulators of the DE genes
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Primary human hepatocytes

DAPI

Primary human
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SNU-182
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Negative control

Normal liver
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TAF 2

Figure 2.5: TAF2 is over expressed in HCC cell lines and HCC liver (a) Representative
fluorescent confocal micrographs showing TAF 2 protein expression in primary human
hepatocytes and different HCC cell lines. (b) A western blot showing the levels of TAF 2
protein expression in primary human hepatocytes and different HCC cell lines.
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(b)
(a)

(d)

(c)

Figure 2.6: TAF2 is knocked down at mRNA and protein levels in cells treated with shRNA
targeting TAF2 mRNA.
(a) A q-RT-PCR showing the levels of TAF2 mRNA expression in untreated Huh7 cells, Huh7
cells treated with control shRNA and Huh 7cells treated with TAF2 shRNA.
(b) A western blot showing the levels of TAF2 protein expression in untreated Huh7 cells, Huh7
cells treated with control shRNA and Huh 7 cells treated with TAF2 shRNA.
(c) A q-RT-PCR showing the levels of TAF2 mRNA expression in untreated QGY-7703 Luc cells,
QGY-7703 Luc cells treated with control shRNA and QGY-7703 Luc cells treated with TAF2
shRNA.
(d) A western blot showing the levels of TAF2 protein expression in untreated QGY-7703 cells,
QGY-7703 cells treated with control shRNA and QGY-7703 cells treated with TAF2 shRNA.
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Figure 2.7: TAF2 knockdown does not affect cellular proliferation.
A bar graph showing absorbance at 600 nm for (a) shCon-1, shTAF2-1 and shTAF2-2
and (b) shCon-2 and shTAF2-3 cells at four time points (24, 48, 72, 96 hours).
(c) Representative colony formation plates (shCon-1 and shTAF2-2) after fixation and
staining.
A bar graph showing colony forming efficiency of (d) shCon-1, shTAF2-1 and shTAF2-2
and (e) shCon-2 and shTAF2-3 cells.
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(a)
(b)

(c)

(d)

Figure 2.8: Stable TAF2 knockdown results in decreased migration
Representative wound healing in (a) shCon-1 and shTAF2-2 and (b) shCon-2 and
shTAF2-3 cells after 24 and 48 hours
(c) A bar graph representing wound distance of (a) shCon-1, shTAF2-1 and shTAF2-2
and (b) shCon-2 and shTAF2-3 cells after 24 and 48 hours
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(a)

(b)

(c)

Figure 2.9: Stable TAF2 knockdown results in decreased invasion.
(a) Pictomicrograph of invaded cells in shCon-1, shTAF2-1, shTAF2-2, shCon-2
and shTAF2-3.
(b) A bar graph showing number of invading cells in (b) shCon-1, shTAF2-1 and
shTAF2-2 and (c) shCon-2 and shTAF2-3 cells.
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Figure 2.10: A western blot showing E-Cadherin, N-Cadherin, Snail, cyclin A and cyclin
B1 protein levels in shCon-1, shTAF2-1 and shTAF2-2 cells
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CHAPTER 5
DISCUSSION AND FUTURE DIRECTION

AEG-1 is a well-established oncogene which is overexpressed in many common cancers.
Its expression level negatively correlates with poor survival and overall adverse
prognosis. A pan cancer analysis of gene expression data in multiple databases identified
TATA-box binding protein associated factor 2 (TAF2) as the gene that is most frequently
co-expressed with AEG1. Human AEG1 gene is present in the chromosomal location
8q22.1 and TAF2 is present in the chromosomal location 8q24.1. The 8q22-24 is a region
that is amplified in many cancers. The fact that these two genes are overexpressed to the
same level in cancer and present in the chromosomal region which is a mutational hotspot
for amplifications indicates that these two genes could possibly be co-amplified during
cancer.

Bioinformatic analyses have showed that levels of TAF2 overexpression positively
correlates with AEG1 overexpression levels in different HCC datasets. These two genes
could be working in cooperation with one another or have the same regulatory
mechanism. It is known that AEG-1 is transcriptionally regulated by c-Myc, an oncogene
frequently upregulated in HCC. It is possible that TAF2 is also a downstream target of cMyc. Data analysis from TCGA database shows that TAF2 is altered in 20% of liver
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cancer patients. As expected, majority of these alterations are amplifications. Comparison
of copy number differences of the TAF2 gene between HCC samples and normal liver
and blood samples in two independent datasets showed a significant increase in the copy
number of the TAF2 gene in HCC samples. To determine if this increase in copy number
results in mRNA overexpression, mRNA expression levels were compared between
normal and HCC livers in three independent datasets. We found a significant increase in
TAF2 mRNA levels in HCC liver compared to normal liver. TAF2 was also ranked high
(top 2%, 3% and 7%) among the mRNAs that were differentially expressed between these
samples. It was also observed that TAF2 mRNA overexpression was not observed in
other liver abnormalities like liver injury or cirrhosis. This leads us to the conclusion that
TAF2 overexpression is HCC specific and could be a driver event in HCC. Analysis of a
survival plot generated from HCC dataset in TCGA showed negative correlation between
TAF2 expression and overall survival of HCC patients.

The TCGA dataset was grouped into TAF2high and TAF2low and a heatmap showing the top 50
genes that are differentially regulated between the two groups was generated. This map showed
that most of the genes are overexpressed in the TAF2high group as compared to the TAF2low group.
Canonical pathway analysis by Ingenuity software showed the pathways that are affected by
these differentially expressed genes. The analysis showed that several pro-oncogenic signaling
pathways were upregulated (HGF, IGF-1 and NGF and ERK-5). Oxidative phosphorylation is a
process that is downregulated in cancers since cancer cells are in a state of hypoxia and unable
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to perform oxidative phosphorylation. Instead, they use glycolysis as their preferred source of
energy. eIF2 is a signaling pathway that is required for successful translation of proteins.
Approximately 50 percent of the genes involved in both of these pathways were found to be
downregulated in TAF2high group. The possible upstream regulators of these differentially
regulated genes were determined. Some of the notable activators of these genes include
molecules involved in oncogenic pathways like CD24, MAP4K4, HGF, CCND1 and

VEGF. Inhibition of the tumor suppressor gene RB1 and several miRNAs were identified
to cluster with TAF2high group.

TAF2 is a protein that is involved in transcription of genes by RNA polymerase II. It is a
factor that is dispensable for basal transcription but, required for activated transcription.
The overexpression of TAF2 in HCC patients was confirmed in silico, in vitro (in cell lines)
and in vivo (in liver sections). Stable cell lines with knockdown of TAF2 were created to
check for the effect of the knockdown on various cancer hallmarks like proliferation,
migration and invasion. Two different assays (MTT and colony formation assays) were
performed to compare the proliferation capacity of TAF2 knockdown cell lines and control
cell lines. TAF2 knockdown cell lines did not show a decrease in cellular proliferation. On
performing a wound healing assay to compare the migration capacity of TAF2 knockdown
and control cell lines, the knockdowns showed a delay in wound healing. A Matrigel
invasion assay was then performed to compare the invasion capacity of TAF2 knockdown
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and control cells. TAF2 knockdown cells showed a decreased ability to invade through
the Matrigel. Thus, knockdown of TAF2 did not affect proliferation but, inhibited migration
and invasion.

An earlier study found TAF2 to be involved in regulating cyclin levels (cyclin A and B1)
and hence cell cycle progression. It was shown that transient knockout of TAF2 in HeLa
cells resulted in a decrease in cyclin A and B1 levels and cell cycle arrest in G2/M phases.
Also, cyclin D1 was one of the possible downstream targets of TAF2 identified through
canonical pathway analysis that was performed as a part of this study. Given the above,
it was contradicting that a decrease in cellular proliferation was not seen in the
knockdowns. To explain this, lysates from the knockdowns were probed for cyclins A and
B1. A decrease was not observed in cyclin A or cyclin B1 levels in the knockdowns. This
gives a possible explanation for not seeing a decrease in cellular proliferation in the
knockdowns. But, the reason for not seeing a decrease in cyclin levels in the knockdowns
is yet to be determined. A possible explanation for this is that the stable cell lines used in
this study are TAF2 knockdown cell lines and not TAF2 knockout cells lines. These cells
have 40 to 60 percent TAF2 in them. This remaining TAF2 could be sufficient to keep
cyclin levels normal and help cell cycle progress without any hindrance.

Epithelial Mesenchymal Transition (EMT) plays a key role in a tumor cell obtaining the
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ability to migrate and invade the basement membrane. Inhibition of migration and invasion
was observed in the knockdowns. To determine if there is a reversal of EMT transition
occurring in the knockdowns, the cell lysates were probed for EMT markers E-Cadherin
and N-Cadherin. An increase in E-Cadherin was observed. Unlike typical cadherin
switching, this was not accompanied by a decrease in N-Cadherin. To find the molecule
causing an increase in E-Cadherin levels, the lysates were probed for known regulators
of E-cadherin. Snail, which is a known negative regulator of E-Cadherin was found to
decrease in the knockdowns. Based on our observations, we can conclude that
knockdown of TAF2 decreases Snail levels which causes increase in E-Cadherin thus
making the cells more epithelial and hence unable to migrate and invade.

The phenotypic difference observed in the knockdowns is due to a decrease in Snail
protein level. But, it is yet to be understood how TAF2 causes this decrease in Snail
protein. The knockdowns need to be probed for known regulators of Snail like smad
proteins. Since no decrease in the mesenchymal marker N-Cadherin is seen, it will be
worthwhile probing for other known mesenchymal markers (Vimentin, Fibronectin, Type I
collagen, Laminin 5 and certain integrins). There are other known EMT regulators (Slug,
Snail, Twist, Zeb1 and Zeb2) that can be probed too. This will help reach a conclusion
about the pathway that TAF2 is involved in to promote EMT. Given that we have obtained
a difference in migration and invasion capacity of the cells, staining these cells will
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determine if there is a difference in actin organization.

Also, bioinformatic data obtained from canonical pathway analysis performed during the
beginning of this study helps explain this difference in migration and invasion. mTOR
signaling, which is involved in tumor cell motility, invasion and metastasis121, was found
to be deregulated in TAF2high group. Also, some of the possible downstream regulators
of TAF2 included Rictor which is a component of the mTORC2 signaling complex and
regulates cell migration122, CD24 which is a cell adhesion molecule, MAP4K4 which
controls cell motility123 HGF or scatter factor which is a cell motility inducer124 and VEGF
which is a cell migration inducer125. It is necessary to study if the observed decrease in
invasion and migration is due to any of these factors.

With evidence from previous studies for involvement of TAF2 in cell cycle regulation and
maintaining cyclin levels, it is important to determine if we did not see a difference in
cellular proliferation due to the remaining TAF2 in the cells or because TAF2 does not
regulate cyclins. It is therefore necessary to create a stable clone with complete knock
out of TAF2 and study if a change in cell proliferation, migration and invasion is obtained.
Another future direction of this project would be to create stable clones that over express
TAF2 and study its effect on cellular proliferation, migration and invasion. Performing a
Differential Expression (DE) analysis using RNA-seq to determine the difference in gene
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expression between the knockout and overexpression cell lines will be help gain an
insight into the genes that are affected by TAF2.
In summary, we have shown that TAF2 is important for tumor migration and invasion. It
is a potential oncogene that needs to be further studied to establish its role in
tumorigenesis.
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